Chartwell Investment Partners LLC grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 5.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,107 shares of the company’s stock after purchasing an additional 413 shares during the period. Chartwell Investment Partners LLC’s holdings in Neurocrine Biosciences were worth $714,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the business. Eaton Vance Management boosted its stake in shares of Neurocrine Biosciences by 20.8% during the 4th quarter. Eaton Vance Management now owns 129,434 shares of the company’s stock worth $9,243,000 after acquiring an additional 22,280 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in shares of Neurocrine Biosciences by 106.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,030 shares of the company’s stock worth $864,000 after acquiring an additional 3,628 shares in the last quarter. Standard Life Aberdeen plc bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $16,815,000. Pacer Advisors Inc. bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $327,000. Finally, NumerixS Investment Technologies Inc boosted its stake in shares of Neurocrine Biosciences by 75.2% during the 4th quarter. NumerixS Investment Technologies Inc now owns 3,300 shares of the company’s stock worth $226,000 after acquiring an additional 1,416 shares in the last quarter.
Shares of NBIX stock opened at $84.71 on Wednesday. The company has a quick ratio of 8.24, a current ratio of 8.36 and a debt-to-equity ratio of 0.81. Neurocrine Biosciences, Inc. has a 12 month low of $64.72 and a 12 month high of $126.98. The company has a market capitalization of $7.73 billion, a price-to-earnings ratio of 385.05, a PEG ratio of 27.81 and a beta of 1.87.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Tuesday, February 5th. The company reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a return on equity of 5.06% and a net margin of 4.68%. The company had revenue of $131.49 million during the quarter, compared to the consensus estimate of $132.32 million. During the same quarter last year, the company earned $0.07 EPS. The company’s quarterly revenue was up 39.1% on a year-over-year basis. On average, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 0.13 EPS for the current year.
In other Neurocrine Biosciences news, insider Kyle Gano sold 3,809 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $88.12, for a total value of $335,649.08. Following the completion of the sale, the insider now owns 17,595 shares in the company, valued at approximately $1,550,471.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Charles Gorman sold 7,614 shares of the firm’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $88.16, for a total value of $671,250.24. Following the completion of the sale, the chief executive officer now owns 408,082 shares of the company’s stock, valued at approximately $35,976,509.12. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.
Several brokerages recently weighed in on NBIX. Zacks Investment Research upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating and set a $105.00 target price for the company in a research note on Wednesday, April 10th. Evercore ISI began coverage on Neurocrine Biosciences in a research note on Thursday, April 11th. They set an “outperform” rating for the company. ValuEngine downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. BidaskClub upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Neurocrine Biosciences in a research note on Wednesday, February 6th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $103.48.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Featured Article: What is dollar cost averaging (DCA)?
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.